Genentech (DNA) Said Avastin Plus Interferon Therapy Improved Progression-Free Survival in RCC
Tweet Send to a Friend
Genentech, Inc. (NYSE: DNA) said interim analysis shows that a randomized Phase III clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE